| Literature DB >> 29940918 |
Kyle Fluegge1,2,3, LaShaunda L Malone4, Mary Nsereko5, Brenda Okware5, Christian Wejse6, Hussein Kisingo5, Ezekiel Mupere7, W Henry Boom4,5, Catherine M Stein5,8.
Abstract
BACKGROUND: Appraisal delay is the time a patient takes to consider a symptom as not only noticeable, but a sign of illness. The study's objective was to determine the association between appraisal delay in seeking tuberculosis (TB) treatment and geographic distance measured by network travel (driving and pedestrian) time (in minutes) and distance (Euclidean and self-reported) (in kilometers) and to identify other risk factors from selected covariates and how they modify the core association between delay and distance.Entities:
Keywords: Health services research; Healthcare access; Mycobacterium tuberculosis; Treatment delay
Mesh:
Year: 2018 PMID: 29940918 PMCID: PMC6019214 DOI: 10.1186/s12889-018-5648-6
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Fig. 1Appraisal delay is the time a person takes to evaluate a symptom as a sign of illness. Illness delay is the time the person takes from the first sign of illness until deciding to seek professional medical care. Utilization delay is the time from the decision to seek care until the consult at a health facility. System delay is the time from the first consultation to initiation of treatment. The red arrow indicates the appraisal date, at which time the patient recognizes possible TB as the explanation for his or her symptoms
Fig. 2Dark green paths identify roads. Travel speeds were highlighted around areas including study households (not identified). In order of speeds, highlighted yellow and purple paths indicate higher travel speeds. The yellow square identifies the NTLP clinic. The most variable road speeds in the map are those surrounding this clinic. The Kampala, Uganda digitized base map was sourced from the Uganda Bureau of Statistics in 2009 and displayed in ArcGIS [22]. OpenStreetMap was used to supplement road travel speeds in areas not covered by the digitized maps [23]
Fig. 3There were 984 households enrolled in the study. Of these, 878 (89%) were eligible for analysis. Of these eligible households, 840 (96%) had global positioning system waypoints available, making them eligible for inclusion in the network analysis sample
Symptoms and associated patient self-reported delays
| Symptom | Number of all patients ( | Median (Min, Max) number of days with symptom | Number of patients reporting symptom at min/median/max number of days | ||
|---|---|---|---|---|---|
| Min | Median | Max | |||
| Loss of appetite | 546 (62) | 60 (3, 365) | 1 | 107 | 7 |
| Cough | 875 (99.8) | 90 (0, 999) | 1 | 460 | 2 |
| Chest pain | 596 (68) | 60 (1, 730) | 1 | 99 | 2 |
| Dyspnea | 381 (43) | 40 (0, 999) | 1 | 17 | 1 |
| Fever | 670 (76) | 60 (1, 730) | 1 | 101 | 2 |
| Hemoptysis | 87 (10) | 5 (1, 66) | 13 | 6 | 1 |
| Malaise | 200 (23) | 30 (3, 360) | 1 | 74 | 1 |
| Produce sputum | 858 (98) | 60 (2, 999) | 2 | 153 | 1 |
| Purulent sputum | 665 (76) | 60 (2, 730) | 1 | 122 | 1 |
| Rigors | 48 (5) | 29 (3, 120) | 1 | 1 | 4 |
| Night sweats | 544 (62) | 60 (1, 730) | 3 | 97 | 1 |
| Weight loss | 723 (82) | 60 (2, 730) | 1 | 142 | 1 |
| Abdominal pain | 26 (5) | 30 (1, 365) | 2 | 8 | 2 |
| Adenopathy | 9 (1) | 30 (7, 140) | 2 | 2 | 1 |
| Arthralgia | 72 (8) | 30 (2, 365) | 1 | 28 | 1 |
| Back pain | 23 (3) | 30 (7, 365) | 3 | 6 | 1 |
| Bone pain | 8 (1) | 45 (9, 250) | 1 | 0 | 1 |
| Confusion | 0 (0) | . | . | . | . |
| Diarrhea | 32 (6) | 14 (1, 112) | 1 | 8 | 1 |
| Dizziness | 7 (1) | 30 (1, 30) | 1 | 5 | 5 |
| Headache | 34 (4) | 30 (1, 150) | 2 | 12 | 1 |
| Myalgia | 27 (3) | 30 (3, 365) | 1 | 6 | 2 |
| Nausea | 4 (0.7) | 14 (4, 60) | 1 | 2 | 1 |
| Pruritis | 8 (1) | 33.5 (7, 360) | 4 | 0 | 1 |
| Rash | 6 (1) | 30 (7, 360) | 2 | 2 | 1 |
| Vision loss | 0 (0) | . | . | . | |
| Vomiting | 25 (4) | 20 (1, 180) | 1 | 1 | 1 |
| Other | 25 (4) | 42.5 (3, 720) | 1 | 0 | 1 |
Fig. 4The expected delay (in days) was calculated for each patient under each model scenario. The per-patient probability that this expected value was contained in the observed delay interval was derived. The means of both outcomes are shown in the figure. Bars represent one standard error from the mean. Abbreviations: MV, multivariable model; MV + MH, multivariable model with multiplicative heteroscedasticity
Multivariable associations with appraisal delay interval (in days) using multiplicative heteroscedasticity
| Treatment-seeking characteristic | Change in # of days’ delay (95% CI) | P | Change in variance of days’ delay (95% CI) | P |
|---|---|---|---|---|
| Geographic distance | ||||
| Pedestrian network travel time (min) | −0.05 (−0.41, 0.32) | 0.79 | 0.009 (− 0.002, 0.02) | 0.10 |
| Driving network travel time (min) | 0.25 (0.05, 0.47) | 0.02 | 0.003 (−0.002, 0.01) | 0.25 |
| Euclidean distance (km) | −2.54 (−10.3, 5.24) | 0.52 | −0.32 (− 0.56, − 0.06) | 0.02 |
| Self-reported distance (km) | 0.95 (− 0.13, 2.02) | 0.09 | 0.01 (− 0.01, 0.04) | 0.30 |
| Predisposing factors | ||||
| Age (in years) | 0.64 (0.31, 0.98) | <.001 | 0.02 (0.01, 0.03) | <.001 |
| Enabling Factors | ||||
| Education (years) | −0.50 (−1.16, 0.16) | 0.14 | −0.02 (− 0.03, 0.002) | 0.08 |
| Need factors | ||||
| Perceived by patient | ||||
| Cough most recent symptom | ||||
| Yes | 13.35 (4.67, 22.02) | 0.003 | 0.50 (0.29, 0.70) | < 0.001 |
| No | Ref | Ref | ||
| Need factors | ||||
| Evaluated by doctor | ||||
| BMI | −0.54 (−1.36, 0.28) | 0.20 | −0.03 (− 0.05, −.004) | 0.02 |
| HIV Status | ||||
| Positive | −0.70 (−7.2, 5.83) | 0.83 | 0.05 (−0.16, 0.26) | 0.66 |
| Negative | Ref | Ref | ||
| Cavitary disease | ||||
| Yes | 8.99 (2.20, 15.79) | 0.009 | 0.31 (0.09, 0.53) | 0.006 |
| No | Ref | Ref | ||
| Cavitary disease extenta | ||||
| Far advanced | 3.29 (−8.90, 15.48) | 0.60 | −0.23 (−0.55, 0.11) | 0.18 |
| Moderately advanced | −5.13 (−16.03, 5.79) | 0.36 | −0.18 (− 0.49, 0.12) | 0.23 |
| Normal or Minimal | Ref | Ref | ||
| AFB Grade smear | ||||
| 3+ = 3 | −1.0 (−12.43,10.45) | 0.86 | −0.05 (− 0.48, 0.38) | 0.83 |
| 2+ = 2 | 6.21 (−7.6, 20.03) | 0.38 | 0.49 (0.002, 0.98) | 0.05 |
| 0–1+ = 1 | Ref | Ref | ||
| Culture result | ||||
| 50+ colonies | 12.49 (5.01, 19.97) | 0.001 | 0.41(0.16, 0.66) | 0.002 |
| 30–49 colonies | 13.63 (4.17, 23.10) | 0.005 | 0.32 (0.003, 0.62) | 0.05 |
| 0–29 colonies | Ref | Ref | ||
| Constant | 39.5 (25.3, 55.7) | < 0.01 | 3.17 (2.67, 3.66) | < 0.001 |
aReference group comprised normal (N = 28) and minimal (N = 73) cavitary disease
Ref Reference category
Bivariate associations with delay interval (in days)
| Treatment-seeking characteristic | Overall median or frequency (%) ( | Marginal change in number of days’ delay (95% CI) | P |
|---|---|---|---|
| Geographic distance | |||
| Pedestrian network travel time (minutes) ( | |||
| Median (IQR) [Min/Max] | 74.6 (56.0) [7.4/236.0] | 0.05 (−0.05, 0.15) | 0.35 |
| Driving network travel time (minutes) ( | |||
| Median (IQR) [Min/Max] | 47.3 (25.9) [5.7/158.5] | 0.13 (−0.05, 0.30) | 0.16 |
| Euclidean distance (kilometers) ( | |||
| Median (IQR) [Min/Max] | 2.78 (2.36) [0.24/10.78] | 0.78 (−1.24, 2.80) | 0.45 |
| Self-reported distance ( | |||
| Median (IQR) [Min/Max] | 5 (5) [0/20] | 0.87 (−0.18, 1.92) | 0.10 |
| Predisposing factors | |||
| Sex | |||
| Male | 464 (53%) | −3.32 (−9.65, 3.0) | 0.30 |
| Female | 414 (47%) | Ref | |
| Age (in years) | |||
| Median (IQR) [Min/Max] | 27 (12) [18/80] | 0.60 (0.03, 1.12) | 0.04 |
| Married | |||
| Yes | 406 (46%) | 3.04 (−3.34, 9.43) | 0.35 |
| No | 472 (54%) | Ref | |
| Tribe | |||
| Buganda | 496 (56%) | −1.86 (−8.21, 4.49) | 0.57 |
| Other | 382 (44%) | Ref | |
| Religion | |||
| Roman Catholic (RC) | 273 (31%) | −3.26 (−13.2, 6.63) | 0.52 |
| Anglican | 263 (30%) | 7.10 (−4.2, 18.5) | 0.22 |
| Muslim | 203 (23%) | −0.82 (−11.1, 9.5) | 0.88 |
| Other | 138 (16%) | Ref | |
| Enabling Factors | |||
| Education (years) ( | |||
| Median (IQR) [Min/Max] | 11 (7) [1/17] | −0.75 (−1.51, 0.02) | 0.06 |
| Household size ( | |||
| Median (IQR) [Min/Max] | 3 (3) [1/30] | −0.05 (− 1.76, 1.66) | 0.96 |
| Person/room | |||
| Median (IQR) [Min/Max] | 2.5 (2.43) [0/14] | −0.18 (−2.05, 1.69) | 0.85 |
| Windows/room | |||
| Median (IQR) [Min/Max] | 0.8 (1) [0/2.5] | −0.35 (−6.47, 5.78) | 0.91 |
| Type of residence | |||
| Muzigo | 613 (70%) | −1.43 (−8.59, 5.71) | 0.70 |
| Other | 265 (30%) | Ref | |
| Need factors | |||
| Perceived by patient | |||
| Cough most recent symptom | |||
| Yes | 158 (18%) | 15.49 (6, 25) | 0.001 |
| No | 720 (82%) | Ref | |
| Total number of symptoms ( | |||
| Median (IQR) [Min/Max] | 7 (3) [0/23] | −0.68 (−1.71, 0.35) | 0.20 |
| Need factors | |||
| Evaluated by doctor | |||
| Modified Bandim TB score | |||
| Median (IQR) [Min/Max] | 6 (2) [0/12] | 0.31 (−1.40, 2.01) | 0.73 |
| TST Cut-off 10 mm | |||
| Positive | 644 (85%) | −4.03 (−16.3, 8.27) | 0.52 |
| Negative | 111 (15%) | Ref | |
| BCG Vaccination | |||
| Yes | 492 (65%) | 2.52 (−2.51, 7.56) | 0.33 |
| No | 264 (35%) | Ref | |
| BMI ( | |||
| Median (IQR) [Min/Max] | 19 (3.2) [12.4/35.5] | −0.83 (−1.83, 0.16) | 0.10 |
| HIV Status | |||
| Positive | 265 (30%) | −5.65 (−12.2, 0.86) | 0.09 |
| Negative | 612 (70%) | Ref | |
| Index Karnofsky | |||
| ≥ 80 | 798 (91%) | 0.11 (−0.38, 0.60) | 0.66 |
| < 80 | 80 (9%) | Ref | |
| Cavitary disease | |||
| Yes | 539 (63%) | 9.50 (3.30, 15.70) | 0.003 |
| No | 321 (37%) | Ref | |
| Cavitary disease extenta | |||
| Far advanced | 455 (53%) | 10.47 (1.04, 19.90) | 0.03 |
| Mod advanced | 304 (35%) | 0.45 (−9.43, 10.33) | 0.93 |
| Normal or Minimal | 101 (14%) | Ref | |
| AFB Grade smear | |||
| 3+ | 713 (81%) | 11.12 (2.3, 19.94) | 0.01 |
| 2+ | 106 (12%) | 12.29 (−2.4, 27)) | 0.10 |
| 0–1+ | 59 (7%) | Ref | |
| Culture result | |||
| 50+ colonies | 588 (68%) | 9.03 (−0.3, 18.35) | 0.06 |
| 30–49 colonies | 155 (18%) | 9.17 (−2.5, 20.84) | 0.12 |
| 0–29 colonies | 128 (15%) | Ref | |
| Personal health behaviors | |||
| Smoking | |||
| Current or former smoker | 164 (19%) | 5.29 (−1.3, 11.85) | 0.12 |
| Never smoke | 713 (81%) | Ref | |
| Alcohol intake | |||
| Yes | 204 (23%) | −4.06 (−10.6, 2.44) | 0.22 |
| No | 673 (77%) | Ref | |
Ref Reference category, TST tuberculin skin test
aReference group comprised normal (N = 28) and minimal (N = 73) cavitary disease